Yang Xiao-Xia, Hu Ze-Ping, Xu An-Long, Duan Wei, Zhu Yi-Zhun, Huang Min, Sheu Fwu-Shan, Zhang Qiang, Bian Jin-Song, Chan Eli, Li Xiaotian, Wang Jian-Cheng, Zhou Shu-Feng
Department of Pharmacy, Faculty of Science, National University of Singapore, Science Drive 4, Singapore 117543.
J Pharmacol Exp Ther. 2006 Oct;319(1):82-104. doi: 10.1124/jpet.106.103606. Epub 2006 Jun 30.
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin) (CPT-11)-based chemotherapy. A recent pilot study indicates that thalidomide attenuates the toxicity of CPT-11 in cancer patients. This study aimed to investigate whether coadministered thalidomide modulated the toxicities of CPT-11 and the underlying mechanisms using several in vivo and in vitro models. Diarrhea, intestinal lesions, cytokine expression, and intestinal epithelial apoptosis were monitored. Coadministered thalidomide (100 mg/kg i.p. for 8 days) significantly attenuated body weight loss, myelosuppression, diarrhea, and intestinal histological lesions caused by CPT-11 (60 mg/kg i.v. for 4 days). This was accompanied by inhibition of tumor necrosis factor-alpha, interleukins 1 and 6 and interferon-gamma, and intestinal epithelial apoptosis. Coadministered thalidomide also significantly increased the systemic exposure of CPT-11 but decreased that of SN-38 (7-ethyl-10-hydroxycampothecin). It significantly reduced the biliary excretion and cecal exposure of CPT-11, SN-38, and SN-38 glucuronide. Thalidomide hydrolytic products inhibited hydrolysis of CPT-11 in rat liver microsomes but not in primary rat hepatocytes. In addition, thalidomide and its major hydrolytic products, such as phthaloyl glutamic acid (PGA), increased the intracellular accumulation of CPT-11 and SN-38 in primary rat hepatocytes. They also significantly decreased the transport of CPT-11 and SN-38 in Caco-2 and parental MDCKII cells. Thalidomide and PGA also significantly inhibited P-glycoprotein (PgP/MDR1), multidrug resistance-associated protein (MRP1)- and MRP2-mediated CPT-11 and SN-38 transport in MDCKII cells. These results provide insights into the pharmacodynamic and pharmacokinetic mechanisms for the protective effects of thalidomide against CPT-11-induced intestinal toxicity.
剂量限制性腹泻和骨髓抑制影响了基于伊立替康(7-乙基-10-[4-[1-哌啶基]-1-哌啶基]羰氧基喜树碱)(CPT-11)化疗的疗效。最近一项初步研究表明,沙利度胺可减轻CPT-11对癌症患者的毒性。本研究旨在使用多种体内和体外模型,探讨联合使用沙利度胺是否能调节CPT-11的毒性及其潜在机制。监测腹泻、肠道病变、细胞因子表达和肠上皮细胞凋亡情况。联合使用沙利度胺(腹腔注射100 mg/kg,共8天)可显著减轻CPT-11(静脉注射60 mg/kg,共4天)所致的体重减轻、骨髓抑制、腹泻和肠道组织学病变。同时,肿瘤坏死因子-α、白细胞介素1和6以及干扰素-γ的表达受到抑制,肠上皮细胞凋亡也受到抑制。联合使用沙利度胺还可显著增加CPT-11的全身暴露量,但降低SN-38(7-乙基-10-羟基喜树碱)的全身暴露量。它可显著减少CPT-11、SN-38和SN-38葡萄糖醛酸苷的胆汁排泄和盲肠暴露量。沙利度胺水解产物可抑制大鼠肝微粒体中CPT-11的水解,但对原代大鼠肝细胞无此作用。此外,沙利度胺及其主要水解产物,如邻苯二甲酰谷氨酸(PGA),可增加原代大鼠肝细胞中CPT-11和SN-38的细胞内蓄积。它们还可显著降低Caco-2和亲本MDCKII细胞中CPT-11和SN-38的转运。沙利度胺和PGA还可显著抑制MDCKII细胞中P-糖蛋白(PgP/MDR1)、多药耐药相关蛋白(MRP1)和MRP2介导的CPT-11和SN-38转运。这些结果为沙利度胺对CPT-11诱导的肠道毒性的保护作用的药效学和药代动力学机制提供了见解。